SAN DIMAS, CALIFORNIA — December 28, 2020 — COVID-19 testing startup Curative rolls out a new SARS-CoV-2 antibody test collected via oral collection pad, as well as the deployment of Influenza A/B vaccinations at multiple COVID-19 testing locations.
While most SARS-CoV-2 antibody tests require a blood draw at a clinic, Curative’s antibody test is self-collected via an oral fluid sample with an easy-to-use oral collection pad. The entire collection process takes three to five minutes and reduces exposure for healthcare workers.
“We’re excited to offer another simple, painless and effective option for people who need COVID-19 testing,” said Fred Turner, CEO and co-founder of Curative. “By simplifying antibody tests and making them available at our testing sites, we hope to increase access to testing for all so that people can better understand if they have had a past infection.”
Curative’s lab-developed antibody detection test helps identify individuals who have Immunoglobulin G (IgG), Immunoglobulin A (IgA), and/or Immunoglobulin M (IgM) antibodies to SARS-CoV-2, the virus that causes COVID-19. Curative’s antibody test provides results within 48 hours upon receipt at the labs, with a sensitivity of 93% and specificity of 100%. This type of test is intended for individuals who believe they may have had a past infection of COVID-19 and do not currently have symptoms.
“As Curative expands our capabilities and product lines, we are also pleased to announce that our sites will deploy Influenza A/B vaccinations during this crucial moment in the current public health pandemic,” said Turner. “Our team is dedicated to making sure patients across the country get both the protection from and access to COVID-19 testing that they need in the most efficient and safest way possible.”
With influenza and respiratory disease season at its peak, patients with Influenza A/B and COVID-19 can experience similar symptoms, including cough, fever, chest tightness, and body aches. Reducing the percentage of people who could potentially end up in the ICU with the widely available flu vaccine will help reduce the stress already placed on the hospital systems by the COVID-19 pandemic. The flu vaccine will be distributed across Curative sites in California, Texas and Florida beginning this week.
Curative’s rollout of the Influenza A/B vaccine and the anti-SARS-CoV-2 antibody test, in addition to its existing COVID-19 PCR testing, demonstrates the continued commitment to protecting lives and reducing strain on the healthcare system. Curative nationwide sites provide various offerings, visit curative.com to learn more about what offerings are available at testing sites near you.
Curative is a leader in on-demand public health service programs and infrastructure. From rapid, mass-scale testing for COVID-19 to other essential services, Curative partners with communities to strengthen public health services with turn-key programs, easy-to-access experiences, and scalable infrastructure, keeping people everywhere safe, healthy, and informed. Co-founded by CEO Fred Turner and comprised of a team of doctors, scientists, engineers, and health industry experts, Curative began COVID-19 testing in early March 2020 upon realizing the urgent need for test development and production in the United States. With a growing network of over 10,000 sites across 15 states and three certified, high-capacity labs, Curative is on track for providing 1M COVID tests a week and rolling out a suite of other services in partnership with major cities, states, and organizations across the US. For more details on Curative, please visit curative.com and follow on F acebook, Instagram, and Twitter.
Curative Inc. and its subsidiary, Curative Management Services LLC, engage with medical entities that provide vaccination services.